Please login to the form below

Not currently logged in
Email:
Password:

Hunter syndrome

This page shows the latest Hunter syndrome news and features for those working in and with pharma, biotech and healthcare.

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

It’s scheduled for regulatory approval in 2020. TAK-609 for Hunter syndrome:TAK-609 (formerly  SHP609) is a new intrathecal formulation of Takeda’s existing intravenous Hunter syndrome therapy Elaprase ... including Dravet syndrome, and is tipped

Latest news

More from news
Approximately 3 fully matching, plus 25 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....